Long-Acting Lipoglycopeptides for the Treatment of Bone and Joint Infections
Authors:
- 1 October 2021
- journal article
- review article
- Published by SAGE Publications in Surgical Infections
- Vol. 22 (8) , 771-779
Abstract
Background: The long-acting lipoglycopeptides dalbavancin and oritavancin possess excellent microbiologic activity against gram-positive bacteria and provide prolonged tissue exposure at sites of infection. Moreover, these antibiotics are well tolerated and do not require therapeutic drug monitoring. Methods: Pharmacokinetic/pharmacodynamic experiments ascertained that one to two doses of these long-acting agents can provide an extended period (≥6 weeks) of antimicrobial therapy. Results: Clinical studies subsequently found that microbiologic and clinical response rates with these agents were comparable to standard antibiotic agents used in the treatment of bone and joint infections. In addition, pharmacoeconomic analyses have discovered cost savings with the use of these antimicrobial agents in the treatment of serious deep-seated bacterial infections. Conclusions: Thus, these long-acting lipoglycopeptides offer potential for cost-effective outpatient parenteral antibiotic therapy of difficult to treat infections, such as osteomyelitis.Keywords
This publication has 42 references indexed in Scilit:
- Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin InfectionsNew England Journal of Medicine, 2014
- Influence of the Protein Kinase C Activator Phorbol Myristate Acetate on the Intracellular Activity of Antibiotics against Hemin- and Menadione-Auxotrophic Small-Colony Variant Mutants of Staphylococcus aureus and Their Wild-Type Parental Strain in Human THP-1 CellsAntimicrobial Agents and Chemotherapy, 2012
- Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycinJournal of Antimicrobial Chemotherapy, 2009
- Oritavancin Kills Stationary-Phase and BiofilmStaphylococcus aureusCells In VitroAntimicrobial Agents and Chemotherapy, 2009
- In Vivo Pharmacodynamic Activity of the Glycopeptide DalbavancinAntimicrobial Agents and Chemotherapy, 2007
- Pharmacokinetic-Pharmacodynamic Relationships Describing the Efficacy of Oritavancin in Patients with Staphylococcus aureus BacteremiaAntimicrobial Agents and Chemotherapy, 2006
- Cellular Pharmacokinetics and Pharmacodynamics of the Glycopeptide Antibiotic Oritavancin (LY333328) in a Model of J774 Mouse MacrophagesAntimicrobial Agents and Chemotherapy, 2004
- Antibiotic treatment of Gram-positive bone and joint infectionsJournal of Antimicrobial Chemotherapy, 2004
- Quantitative Analysis of Gentamicin, Azithromycin, Telithromycin, Ciprofloxacin, Moxifloxacin, and Oritavancin (LY333328) Activities against Intracellular Staphylococcus aureus in Mouse J774 MacrophagesAntimicrobial Agents and Chemotherapy, 2003
- Pharmacodynamics of Oritavancin (LY333328) in a Neutropenic-Mouse Thigh Model of Staphylococcus aureus InfectionAntimicrobial Agents and Chemotherapy, 2003